Chitosan and chitin-derived biomaterials, including native chitosan and chemically modified derivatives, have been widely investigated across orthopedic tissue engineering, implant functionalization, infection control, local delivery, and interface repair, but the evidence is dispersed across heterogeneous formats and indications. This single-author structured narrative review synthesizes 258 unique publications and interprets chitosan through a polymer design, quantitative performance, and clinical translation framework. Literature was identified (January–May 2026) using PubMed/MEDLINE as the primary database, with targeted verification in Web of Science, Scopus, and Google Scholar; no formal risk-of-bias or certainty grading was performed. Chitosan was studied as scaffolds, hydrogels, coatings, nanoparticles, microspheres, fibers, bioadhesives, bone-cement additives, cartilage adjuncts, tendon-to-bone systems, and intervertebral disk biomaterials. The highest human clinical evidence supported BST-CarGel/chitosan–blood implant augmentation of knee marrow stimulation, where randomized, 5-year, and biopsy data favored structural repair over microfracture alone; most other applications—bone regeneration, coatings, osteomyelitis hydrogels, bone cements, tendon/rotator cuff systems, and disk biomaterials—remain preclinical or translational-preclinical. Chitosan should be interpreted as a tunable polymer platform, not a single material; translation requires chemistry-defined formulation, indication-specific mechanical qualification, clinically relevant comparators, and standardized reporting.
Furkan Yapıcı (Wed,) studied this question.